Evaluation of a new commercial von Willebrand factor multimer assay

Preclinical evaluation of a semi‐automated and rapid commercial electrophoresis assay for von Willebrand factor multimers

“…Recently, the Sebia method was extensively evaluated by other authors, who provided positive comments on the fundamental consistency of the obtained data and presented reports at international meetings . The same group of scientists additionally published a chapter on VWF multimers in the book available from Springer Science + Business Media (Hemostasis and Thrombosis: Methods and Protocols, Methods in Molecular Biology, vol.…”

Postanalytical considerations that may improve the diagnosis or exclusion of haemophilia and von Willebrand disease

“…In this review, we have provided some guidance for laboratories involved in testing factor levels and VWF, or otherwise employed for assessing the possibility of haemophilia or VWD in patients with “suspected bleeding disorders”. The suggested “postanalytical” considerations are aimed to reduce the risk of misdiagnosis of haemophilia/VWD and supplements our previous discussions around associated preanalytical and analytical considerations . In addition to these, it may also be pertinent to include additional comments around other potential preanalytical events as relevant to each specific case.…”

“…Analytical testing procedures for haemophilia and VWD are also detailed elsewhere . The risk of analytical errors has been substantially lowered in modern times because of the robustness of modern instrumentation.…”

“…18 Analytical testing procedures for haemophilia and VWD are also detailed elsewhere. 8,9,14,[19][20][21][22][23][24][25][26][27][28][29][30][31] The risk of analytical errors has been substantially lowered in modern times because of the robustness of modern instrumentation. Thus, test results as reported to clinicians usually reflect accurate measurements of the analyte for the presented sample (eg in a recent report, the overall analytical error rate for individual tests associated with VWD diagnosis was <0.5%, meaning very few errors are associated with analytical failures).…”

“…considerations are aimed to reduce the risk of misdiagnosis of haemophilia/VWD and supplements our previous discussions around associated preanalytical and analytical considerations. [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28] In addition to these, it may also be pertinent to include additional comments around other potential preanalytical events as relevant to each specific case. For example, as discussed in our earlier report, 18 The laboratory may be able to assess this further by specific testing for rheumatoid factor or HAMA, or by testing VWF:Ag using another methodology less likely to be affected by such interfering substances (eg enzyme linked immunosorbent assays).…”